Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy  by Caforio, Alida L.P. et al.
Autoimmune disease is characterized by the presence of 
circulating autoantibodies (1). In nonorgan-specific autoim- 
mune disease, the autoantibodies are against ubiquitous 
autoantigens (for example, nuclear antigens in systemic 
lupus erythematosus). In organ-specific autoimmunity, the 
autoantibodies react with autoantigens that are unique to the 
target tissue (for example, thyroid peroxidase in Washimo- 
to’s thyroiditis and other autoimmune thyroid diseases) (2). 
An autoimmune mechanism may be involved in the 
pathogenesis of dilated cardiomyopathy, an idiopathic heart 
From the *Department of Cardiological Sciences, St. George’s Wospital 
Medical School and Kkpartment of Immunology, University College & 
Middlesex School of Medicine, London, England and SCNR Institute of 
Clinical Physiology, Pisa, Italy. 
Manuscript received September 18, 1989; revised manuscript received 
December 13, 1989, accepted January 3, 1990. 
-far Alida L. P. Caforio, MD, Department of Cardiolog- 
ical Sciences, St. George’s Hospital Medical School, Cranmer Terrace, 
London SW17 ORE, England. 
muscle disorder that is characterized by progressive myo- 
cyte destruction, ultimately leading to fibrosis (3). Conclu- 
sive evidence of organ-specific cardiac antibodies would 
strongly support this hypothesis. The involvement of organ- 
specific autoimmunity in dilated cardiomyopathy remains 
controversial (4,5). Previous studies using indirect immuno- 
fluorescence, the reference technique for the detection of 
organ-specific autoantibodies (6,7), revealed cardiac anti- 
bodies in dilated cardiomyopathy (8-1% but their true organ 
. . 
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antibodies cross-reacted with skeletal muscle (g-22) and 
were found with a similar frequency in other cardiac condi- 
tions (9,15-22). 
The aim of this study was to establish the frequency of 
organ-specific cardiac autoantibodies using i 
cence in patients with dilated cardiomyopathy compared 
with that in normal subjects and patients with heart failure of 
other etiology or with other cardiac disease. 
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St&y patients. The study group included 65 patients with 
dilated cardiomyopathy, 208 with other cardiac disease, 41 
with chronic heart failure due to myocardial infarction and 
200 healthy blood donors. None of the study patients had 
postpericardiotomy or Dressier’s syndrome. Serum from 2 
ml of blood obtained at the time of routine laboratory tests 
was used for the immunologic studies. 
Dilated cardiomyopathy. These 65 patients were 15 to 70 
years of age (mean 46 2 13); there were 46 men and 19 
women, The diagnosis was made within 2 years of the study 
in 19 patients and after 2 years (up to 13 years) in the 
remaining 46 patients. The diagnosis of dilated cardiomyop 
athy was based on the demonstration of a dilated and poorly 
contracting left or right ventricle, or both, according to 
World Health Organization criteria (23). At the time of 
examination, 15 patients were in New York Heart Associa- 
tion functional class I, 20 were in class II, 27 in class III and 
3 in class IV. Sixty-one patients (94%) were treated with a 
diuretic drug, 42 (65%) with an angiotensin-converting en- 
zyme inhibitor, 31 (48%) with an anticoagulant and 8 (13%) 
with digoxin, 6 of whom were in established atrial fibrllla- 
tion. In all 65 patients, right and left heart catheterization, 
selective coronary arteriography, left ventriculography and 
either two-dimensional echocardiography (n = 54) or radio- 
nuclide angiography (n = 28), or both, was performed. Left 
ventricular end-diastolic and end-systolic echocardiographic 
dimensions were 44 to 85 mm (mean 62 + 10) and 33 to 80 
mm (mean 51 + 12), respectively. Fractional shortening was 
5% to 37% (mean 17 2 7%), left atria1 internal dimension was 
17 to 59 mm (mean 40 f 9) and ejection fraction was 13% to 
50% (mean 31 + 12%). 
Patients were excluded if there was evidence of 1) coro- 
nary heart disease at selective coronary arteriography, 2) 
ischemia during exercise testing, 3) systemic blood pressure 
~150190 mm Hg, 4) concomitant systemic or endocrine 
diseases that are known to cause left ventricular impairment, 
or 5) excessive alcohol consumption, defined as a daily 
intake of at least 8 oz. (0.24 liter) of hard liquor or 2 qt (1.9 
liters) of beer for the preceding 10 years (24). When lesser 
ethanol consumption was documented, only patients in 
whom impaired myocardial performance persisted after eth- 
anol wiidrawal were included; this criterion applied to 14 
patients. 
Other curdiac disease. This group of 208 patients in- 
cluded 67 with coronary heart disease, 43 with hypertrophic 
cardiomyopathy, 36 with long-standing rheumatic heart dis- 
ease, 24 with idiopathic ventricular tachycardia of right 
ventricular origin and 38 with congenital heart disease, All 
Patients underwent clinical assessment and two-dimensional 
echocardiography; in all patients with idiopathic ventricular 
tachy=dia. coronary heart disease, rheumatic heart disease 
or congenital heart disease, right and left heart catheteriza- 
tion, selective coronary arteriography and left ventriculog- 
raphy were performed. 
The 67 patients in the coronary heart disease group were 
56 -c 10 years of age; there were 60 men and 7 women. 
Thirty-one patients (47%) underwent coronary artery bypass 
graft surgery within 1 week of serum sampling. 
The 43 patients with hypertrophic cardiomyopathy were 
44 f 14 years of age; there were 26 men and 17 women. The 
diagnosis was based on typical clinical, hemodynamic and 
angiographic features and the demonstration of unexplained 
left ventricular ~y~e~~op~y (25). 
In the rheumatic heart disease group, the 36 patients 
were 59 + 13 years of age; there were 12 men and 24 women, 
with a duration of symptoms of 5 to 15 years (median 10). 
Twenty patients had mitral valve disease, 14 had aortic valve 
disease and 2 had both. None had active rheumatic carditis. 
Eighteen patients (50%) underwent valve replacement, and 
in all a rheumatic etiology was confirmed at histopathologic 
analysis of the excised valves. 
The 24 patients with idiopathic ventricular tachycardia of 
right ventricular origin were 42 r 12 years of age; there were 
14 men and 10 women. All had normal echocardiographic 
and angiographic left ventricular structure and function and 
were selected from a well characterized group of patients 
(26). 
The 38patients with congenital heart disease were 1 to 67 
years of age (median 11); there were 25 men and 13 women. 
Control patients with heart failure. Forty-one patients 
who had had a documented ial infarct 6 months to 
10 years (median 2 years) sly were selected as 
control patients with chronic heart failure. They were 47 5 
12 years of age; there were 28 men and 13 women. Thirty- 
one patients were in functional class III and 10 were in class 
IV. Thirty-seven (90%) were treated with a diuretic drug, 25 
(60%) with an angiotensin-converting enzyme inhibitor and 4 
(10%) with digoxin. Ejection fraction was 16% to 44% (mean 
30 * 7%). 
Healthy blood donors. These 200 normal subjects were 
35 2 11 years of age; there were 91 men and 109 women. 
screening. Sera were tested by standard 
indirect immunofluorescence technique (7) on 4 pm thick 
unfixed cryostat sections of blood group 0 human atrium, 
ventricle and intercostal skeletal muscle obtained at the time 
of cardiac surgery from patients with congenital heart dis- 
ease. The tissues were snap-frozen in isopentane precooled 
with acetone-solid carbon dioxide mixture within 15 min of 
removal. The frozen tissues were stored at -70°C until used. 
The same heart and skeletal muscle tissues were employed 
until used up. Three sera known to be positive were tested 
and titrated on any new substrate required. Sera were 
diluted l/l0 in pH 7.2 phosphate-buffered saline solution and 
fluorescein isothiocyanate-labeled sheep anti-human immu- 
noglobulin (Wellcome Laboratories) was used at 1160 dilu- 
tion. Sections were viewed on a Zeiss ultraviolet microscope 
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tions of sera in phos 
anti-b~man C3c im 
cut and homogenized for 5 min in 5 volumes of ice-cold 
0.5% aprotimn, usm 
concentration was 
each homogenate preparation and to buffer alone (as a 
control). Abso~tio~ was pe~o~ed ove~igbt at 4°C with 
agitation, and sera we n cleared of particulate residues 
by centrifugation at 1 g for 10 min. The supernatants 
were tested and titrat he cardiac antibody immunoflu- 
orescence assay. A titer reduction of >I doubling dilution 
was considered a positive absorption. 
tog. Sera from all patients 
ypertrophic cardiomyopa- 
thy and the 200 blood donors were screened for islet cell and 
tested by immunofluorescence for nuclear, smooth muscle 
and mitochondrial antibodies on frozen sections of rat liver 
and kidney with the use of standard protocols (28). 
ositive sera co~tai~e 
or ~o~corn~lerne~t fixi 
st~atiofla~ fluorescence 
reactive I (Fig. 2). Their titers ra 
tissue. All positive sera c ined antibodies of IgG class, 
and four also contained antibodies. Antibodies that 
showed a broad striational pattern on ~ongitudina~ sections of 
heart and skeletal muscle were classified as cross-reactive 2 
(Fig. 3). 
0n transverse sections of myofibers, striations were not 
well defined and both cross-reactive antibodies 1 and 2 gave 
a “sarcolemmal-sarcoplasmic” type staining. In addition, a 
peripheral “sarcolemmal” type pattern was often given by 
the second fluoresceinated antibody in the absence of patient 
serum on some heart and skeletal muscle tissues. This 
control tissue. Organ-specific cardiac antibody titers de- 
creased after absorption with heart homogenate, but were 
Figure 1. Organ-specific cardiac antibodies. 
Cryostat sections of blood group 0 human 
atrium (left) and skeletal muscle (Bight) 
stained with a serum from a patient with 
dilate6 cardiomyopathy. A diffuse cytoplas- 
mic immunofluorescence is visible on atrial 
myocytes, but not on skeletal muscle. The 
bright dots in one myocyte (left) are due to 
autofluorescence and probably reflect li- 
pofuscine accumulation. Original magnilica- 
tion x400, reduced by 32%. 
Figure 2. Cross-reactive I (fine striational) 
cardiac antibody. Cryostat sections of blood 
group 0 human atrium (left) and skeletal 
muscle (right) stained with a serum from a 
patient with dilated cardiomyopathy. A fine 
striational immunofluorescence is visible on 
atrial tissue, but skeletal muscle is negative. 
The distinction between fine and broad (see 
Fig. 3) striations on heart tissue can be best 
appreciated by microadjustments of the fo- 
cus of the microscope. Original magnifica- 
tion x400, reduced by 32%. 
Figure 3. Cross-reactive 2 (broad striational) 
cardiac antibody. Cryostat sections of blood 
group 0 human atrium (left) and skeletal 
muscle (right) stained with a serum from a 
patient with rheumatic heart disease. A 
broad striational immunofluorescence is vis- 
ible on both atrium and skeletal muscle. 
This immunofluorescence pattern was first 
reported in serafrom patients with myasthe- 
reduced by 32%. 
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organ specificity of cardiac antibodies by ~uaat~tative 
n studies. Sera containing cardiac a~t~bodies were 
cubated with human heart and skeletal muscle and rat liver ho 
nates. Organ-specific cardiac antibodies were absorbed with 
homogenate only; cardiac anti ies termed cross-reactive I were 
art and skeletal muscle ho 
as cross-reactive 2 were ab- 
homogenate. AHA titer = anti 
anti-heart antibody titer 
P = preabsorption aoti-be~a~ti~y titer; SK = anti-heart anti- 
bady titer after absorption with human skeletal muscle homogenate. 
not affected by incub 
titers in the sera classl 
to the same extent by 
muscle. Cardiac antibo 
reactive 2 were absorbed by human skeletal muscle and to a 
three classified sta 
sorption with rat liver 
Table 1. Prevalence of Circulating Autoantibodies in Cardiac Disease 
myopathy with and without orga 
tricular end-diastolic and end-systolic dimensions in patients 
Cardiac Noncardiac Organ-Specific Nonorgan Specific 
Cardiac- Cross-Reactive 
Specific I and 2 ICA PCA MCHA ANA AMA SMA 
No. (%) No. (%I No. (%I No. (%I No. (%) No. (%) No. (%) No. (%I 
DCM (n = 65) 17 (26)* 7(11) 0 6 (9) 12 (18) 16 (24)t I (2) 0 
IHD (n = 67) 0 4 (6) - - - II (16) 0 2 (2) 
RHD (n = 36) 0 3 (8) - 12 (3315 0 4(11) 
HCM (n = 43) 0 3 (7) 0 2 (5) 4 (9) 6 (14) 0 2 (51 
CHD (n = 38) 1 (3) 3 (8) - - - 8 (8) 0 0 
IVT (II = 24) 1 w 2 #I - II - I (41 0 0 
CkiF (n = 41) 0 I (2) .- - - 6 (15) 0 0 
NBD (n = 200) 7 (3.5) 1 I (5.5) 0 22 (II) 26 (13) 15 (7.5) 2 (I) 24 (12) 
*p C O.UOO1. tp < 0.01. $p c 0.001 versus blood donoJb ANA = antinuclear antibody; AMA = antimitochondrial antibody; CHD = congenital hearl disease; 
CHF = chroaic heart failure; DCM = dilated cardiomyopathy: HCM = hypenrophic cardiomyopathy: ICA = anti-islet cell antibody; IHD = ischemic heart 
disease; IVT = idiopathic ,ventricular tachycardia; MCHA = antithyroid microsomal antibody; NBD = normal blood donors; PCA = antigastric parietal cell 
antibody; RHD = rheumatic heart disease; SMA = smooth muscle antibody; - = not done. 
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with and without these antibodies were similar (17 + 8%, 
64 + 8 mm and 53 + 9 mm versus 18 2 IO%, 62 f 10 mm and 
51 r 10 mm, respectively). 
Org~n-specific cardiac antibodies were more common in 
patients with dilated cardiomyopathy with fewer symptoms 
(8 of 15 in functional class I versus 9 of 50 in class II t0 IV, 
p c 0.01) and with more recent (<2 years) onset of disease 
(9 of 19 versus 8 of 46, p C 0.02). 
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iscussion 
The study reports the first demonstration of organ- 
specific cardiac antibodies by indirect immunofluorescence. 
These antibodies were detected in 26% of a consecutive 
series of patients with dilated cardiomyopathy and were 
virtually absent in patients with other cardiac disease or 
cardiac failure secondary to ischemic heart disease and in 
normal subjects. The detection of these antibodies in low 
frequency in control subjects is in agreement with the 
findings in other organ-specific autoimmune diseases (6,7). 
The prevalence of organ-specific cardiac antibodies was 
significantly higher (53%) among patients with dilated car- 
diomyopathy with fewer symptoms rnd more recent onset of 
disease (~2 years); such antibodies were not seen in patients 
with cardiac failure due to myocardial infarction. These 
results were obtained using indirect immunofluorescence, a 
well validated technique for the detection of organ-specific 
autoantibodies (6,7). The organ specificity of these cardiac 
autoantibodies was confirmed by quantitative absorption 
studies. Whether or not they have a pathogenic role remains 
to be established. 
Inununok @c characteristics and tissue speciEcity of car= 
disc antibo&~s. Organ-specific cardiac antibodies gave a 
diffuse cytoplasmic staining of myocardial cells and were not 
absorbed by human skeletal muscle or rat liver homoge- 
nates. These findings are consistent with the established 
cytoplasmic location of organ-specific autoantigens (7) and 
with experimental studies (29) in which organ-specific cyto- 
plasmic cardiac antibodies developed after immunization 
with heterologous heart tissue. The relatively low titer of 
organ-specific cardiac antibodies is in keeping with the 
findings in other organ-speSfic autoimmune diseases (6,7). 
Previous studies using indirect immunofluorescence have 
shown cardiac antibodies that were described as cytoplas- 
mic, “diffuse” (9,18,21) or “inter-myofibrillary” (8,9,12,16- 
19,21,22,30) in a variety of cardiac diseases including dilated 
cardiomyopathy. These studies did not demonstrate organ 
specificity of these antibodies because absorption studies 
with skeletal muscle and other unrelated tissues were not 
performed (8,9,12,16-17,21,22,30). In the few studies (18,19) 
in which absorption was performed, the immunofluores- 
cence staining on heart sections was abolished after incuba- 
tion with skeletal muscle, indicating that the antibodies were 
not specific for cardiac muscle, although sera from patients 
with dilated cardiomyopathy were not tested. 
In this study, in addition to organ-specific antibodies, 
cross-reactive cardiac antibodies were also detected. Their 
prevalence in patients with dilated cardiomyopat 
and was similar to that observed in the other pati 
These findings are in agreement with previous studies 
(8,17,20,22,30), although the distinction between the fine 
(cross-reactive 1) and broad (cross reactive 2) striational 
pattern has not always been made (8,17,20,22). The former 
gave weak or negative staining on skeletal muscle, 
the latter showed a strong “myasthenic” pattern 
These patterns have already been described and fo 
different both on human skeletal muscle and on glycerinated 
guinea pig muscle fibers (30). Because intercostal skeletal 
muscles were always used in this study, it is unlikely that the 
pattern termed here cross-reactive 1 is an artifact due to 
different isoforms of the contractile proteins in different 
muscles. 
Cardiac autoantibodies with a “sarcolemmal” pattern 
that cross-react with skeletal muscle have been described 
previously (8,9,11,12,14,18,21). A “sarcolem 
was not seen in the study. Because it was obse 
tissues other than fresh normal human heart 
(11,18), it is likely that the “sarcolemmal” pattern was 
caused by heterophile reactions (7). In other studies 
(8,9,12,14,21) using human heart, nonspecific binding of the 
secondary antibody alone might account for it. The orienta- 
tion in which myofibers are cut within the tissue section 
could also be important; others (30) have suggested and our 
experience confirms that “striational” patterns are often 
present as “sarcolemmal” when myofibers are cut transver- 
sally within the tissue section. 
Potential autoantigens. The autoantigens recognized by 
the organ-specific cardiac antibodies detected by immuno- 
fluorescence remain to be identified. At present, several 
potential cardiac-specific autoantigens have been reported 
(32), including mitochondrial antigens such as the adenine 
nucleotide translocator (33), the M7 antigen (34) and the 
cardiac myosin isoform (35). Antibodies against the former 
mitochondrial antigens have been detected in sera from 
patients with dilated cardiomyopathy, using an enzyme- 
linked immunosorbent assay (33,34). The immunofluores- 
cence reactivity of the antibodies against the adenine nucle- 
otide translocator remains to be tested (33), and there was no 
correlation between the presence of antibodies against the 
M7 antigen and the cytoplasmic intermyofibrillary immuno- 
fluorescence pattern (34). The organ specificity of thes 
antigens requires confirmation, particularly because mito- 
chondrial autoantigens are usually not organ specific (28). 
Antibodies against the cardiac myosin isoform have been 
reported in mice (35,36). Antimyosin antibodies have been 
found in a large spectrum of human cardiac disease 
(8,17,22,37,38) as well as in normal individuals (39), but 
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absence 
hations for the 
ation in addition to 
were significantly more 
clinical signs of heart 
disease, and there was a tre 
ecific antibodies. A 
henotype and dilate 
In type 1 diabetes, viral infection is implicated as a precipi- 
tating rather than an initiating factor of beta cell damage (51), 
a concept supported by the demonstration of a long latency 
period preceding the onset of symptoms (5%). The precise 
role of coxsackieviruses in dilated cardiomyopathy remains 
to be established. 
This is the first report using immunofluores- 
cence and orption studies of the presence of organ- 
specific r;ardiac antibodies in a sizable proportion of patients 
with dilated cardiomyopathy. These antibodies are a sero- 
logic marker of organ-specific autoimmunity and, as has 
been the case in other autoimmune disorders, they may be 
and 
iaica 
covertly in progress. 
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